Professor Greenwood trained in physiology at the Institute of Psychiatry, London, where his work focused on the structure and function of the blood-brain barrier (BBB) in health and disease. He then moved to the BBB group at King’s College London. Subsequently, he was awarded the Renee Hock Fellowship at the Institute of Ophthalmology under the mentorship of Professor Sue Lightman. In 1993 he was made senior lecturer and in 2000 he was appointed to the Hugh Davson Chair of Biomedical Research. Between 2008 and 2016 John was Head of the Department of Cell Biology. The main focus of the Greenwood laboratory is to investigate the role the vasculature plays in the onset and progression of diseases such as uveitis, age-related macular degeneration, diabetic retinopathy, multiple sclerosis (MS), and cancer. The overarching aim of this work is to gain insight into the molecular mechanisms of the vasculature that contribute to disease, identify potential therapeutic targets, develop and test therapeutic strategies and eventually translate this into patient trials. Recently his work has resulted in the identification and characterisation of a novel vascular-disrupting and pro-fibrotic factor LRG1 and has led to the development of a therapy targeting this protein in major diseases including cancer, chronic kidney disease, lung disease and ocular disease. A UCL spinout company, Senya Therapeutics, has been formed to commercialise the therapy.